| Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS … YL Wu, D Planchard, S Lu, H Sun, N Yamamoto, DW Kim, DSW Tan, ... Annals of Oncology 30 (2), 171-210, 2019 | 296 | 2019 |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative … K Park, J Vansteenkiste, KH Lee, G Pentheroudakis, C Zhou, K Prabhash, ... Annals of Oncology 31 (2), 191-201, 2020 | 92 | 2020 |
| LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from … BC Cho, E Felip, AI Spira, N Girard, JS Lee, SH Lee, YV Ostapenko, ... Annals of Oncology 34, S1306, 2023 | 57 | 2023 |
| Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study GF Ho, CS Chai, A Alip, MIA Wahid, MM Abdullah, YC Foo, SH How, ... BMC cancer 19, 1-11, 2019 | 47 | 2019 |
| Amivantamab Plus Lazertinib for Previously Untreated EGFR-Mutated Advanced NSCLC J Xi, D Henry | 23 | 2024 |
| Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced nonsmall cell lung cancer (NSCLC): Primary results from MARIPOSA, a … BC Cho, E Felip, AI Spira, N Girard, JS Lee, SH Lee, YV Ostapenko, ... Annals of Oncology 34, S1306-S1306, 2023 | 22 | 2023 |
| Treatment outcome for head and neck squamous cell carcinoma in a developing country: university Malaya medical centre, Malaysia from 2003-2010 YF Wong, MM Yusof, WZW Ishak, A Alip, VCE Phua Asian Pacific Journal of Cancer Prevention 16 (7), 2903-2908, 2015 | 17 | 2015 |
| Management of advanced prostate cancer in a middle‐income country: real‐world consideration of the Advanced Prostate Cancer Consensus Conference 2017 M Saad, A Alip, J Lim, MM Abdullah, FLT Chong, CB Chua, F Ismail, ... BJU international 124 (3), 373-382, 2019 | 14 | 2019 |
| Prognostic factors in patients with non-small cell lung carcinoma and brain metastases: a Malaysian perspective WH Tang, A Alip, M Saad, VCE Phua, H Chandran, YH Tan, YY Tan, ... Asian Pacific Journal of Cancer Prevention 16 (5), 1901-1906, 2015 | 13 | 2015 |
| Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors CS Chai, CK Liam, ME Poh, DBL Ong, YK Pang, PL Cheah, GF Ho, A Alip Cancer management and research, 5439-5450, 2020 | 11 | 2020 |
| Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from … E Felip, BC Cho, V Gutiérrez, A Alip, B Besse, S Lu, AI Spira, N Girard, ... Annals of Oncology 35 (9), 805-816, 2024 | 10 | 2024 |
| Barriers of and strategies for shared decision‐making implementation in the care of metastatic breast cancer: A qualitative study among patients and healthcare professionals in … PY Lee, AT Cheong, SS Ghazali, AA Rashid, SC Ong, SY Ong, A Alip, ... Health Expectations 25 (6), 2837-2850, 2022 | 8 | 2022 |
| The efficacy and tolerability of scalp cooling in preventing chemotherapy-induced alopecia in patients with breast cancer receiving anthracycline and taxane-based chemotherapy … M Saad, FLT Chong, AZ Bustam, GF Ho, RA Malik, WZW Ishak, VCE Phua, ... Indian Journal of Cancer 55 (2), 157-161, 2018 | 7 | 2018 |
| LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup … S Lu, BC Cho, JS Lee, SH Lee, P Danchaivijitr, B Liu, A Alip, H Xiong, ... Annals of Oncology 34, S1661, 2023 | 6 | 2023 |
| Effectiveness of decision aid in men with localized prostate cancer: a multicenter randomized controlled trial at tertiary referral hospitals in an Asia Pacific country NB Jalil, PY Lee, MZ Nor Afiah, KL Abdullah, FNSM Azizi, NNSA Rassip, ... Journal of Cancer Education, 1-10, 2022 | 5 | 2022 |
| Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience NK Abd Ghafar, A Alip, TA Ong, NY Yap, M Saad Journal of Cancer Research and Therapeutics 14 (6), 1303-1311, 2018 | 5 | 2018 |
| Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy IL Lim, AVP Loo, V Subrayan, TF Khang, MH See, A Alip, NAM Taib The Breast 39, 117-122, 2018 | 4 | 2018 |
| Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration‐resistant prostate cancer: real‐world experience in the southeast … J Lim, A Amantakul, N Shariff, B Lojanapiwat, A Alip, TA Ong, ... Cancer Medicine 9 (13), 4613-4621, 2020 | 3 | 2020 |
| Capecitabine pattern of usage, rate of febrile neutropaenia and treatment related death in asian cancer patients in clinical practice VCE Phua, WQ Wong, PL Tan, AZ Bustam, M Saad, A Alip, WZW Ishak Asian Pacific Journal of Cancer Prevention 16 (4), 1449-1453, 2015 | 3 | 2015 |
| Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A … E Felip, BC Cho, V Gutiérrez, A Alip, B Besse, S Lu, AI Spira, N Girard, ... Journal of Clinical Oncology 42 (16_suppl), 8504-8504, 2024 | 2 | 2024 |
